中新网北京10月16日电 (记者张素)"为维持并推动未来增长，企业领袖正将战略投资聚焦人工智能、人 才建设与风险韧性等领域，以期支撑和驱动未来增长。"近日发布的《2025全球首席执行官展望》有此 表述。 这份报告由毕马威发布。报告撰写团队基于对全球1300多位首席执行官的年度调查发现，众多企业正积 极调整增长战略，以应对当前的复杂局势。 （文章来源：中国新闻网） 报告注意到，人工智能在全球的加速普及也给董事会带来新的挑战。首席执行官们对其伦理影响、数据 准备度及监管缺失等关键问题深表忧虑。不过，一个明确的共识正在形成，"健全的治理框架将是人工 智能稳健、可持续发展的基石"。 "我们的调查显示，首席执行官正在通过对于技术、创新、人才的大胆投资，在变革中寻求机遇。"毕马 威国际主席兼首席执行官比尔·托马斯在受访时称，首席执行官对人工智能的回应正是这一点的体 现，"企业领导者认识到他们在拥抱创新的同时，也需要妥善处理对伦理道德、监管、技能提升及人才 获取等方面的担忧。" 报告称，面对不断变化的经济形势，首席执行官正加倍投入人工智能与技术创新。近四分之三的首席执 行官将人工智能列为2026年的重点投资领域，其中，69 ...

中经记者 郝亚娟 夏欣 上海 北京报道 （编辑：张漫游 审核：何莎莎 校对：张国刚） 在调查中，88%的中国首席执行官对未来三年的中国经济发展有信心，占比较去年大幅提升。此外，中 国首席执行官对人工智能的价值认同显著提升：86%的受访者预期可在三年内看到人工智能的投资回 报，远高于去年的18%。 近日，毕马威发布的《2025全球首席执行官展望》显示，首席执行官对全球经济的信心已降至五年来最 低点。在此背景下，为维持并推动未来增长，企业领袖正将战略投资聚焦人工智能、人才建设与风险韧 性等三大领域，以期支撑和驱动未来增长。 这项对全球1300多位首席执行官的年度调查显示：面对持续紧张的地缘政治局势和经济不确定性，首席 执行官对经济前景普遍持谨慎态度。 ...

报告显示，严峻的外部环境挑战正推动企业管理模式发生转变，众多企业正积极调整增长战略，以应对 当前的复杂局势。目前，有68%的首席执行官对当前全球经济走势抱有信心，低于去年的72%。同时， 中国首席执行官们对全球和中国经济发展前景的预期分化显著：对未来三年全球经济增长较有信心的中 国首席执行官占比为58%，较去年大幅下降13个百分点；而88%对未来三年中国经济发展有信心，较去 年大幅提高17个百分点，并创近年新高。 毕马威中国主席邹俊表示，今年的调查结果显示，首席执行官们对全球经济的信心出现下降，但对自身 企业的发展信心依然稳固。这一反差体现了企业战略重心从外部环境向内生动力的转移——通过对人工 智能、组织变革与风险韧性的战略性投入，主动构筑发展"护城河"，实现从 "生存韧性"向 "发展韧 性"的跃迁。在此背景下，中国经济在重重考验中稳步向前，特别是一系列增量政策的落地实施有效提 振了社会预期。 北京商报讯（记者 马换换 王蔓蕾）近日，毕马威发布的《2025全球首席执行官展望》报告显示，为维 持并推动未来增长，企业领袖正将战略投资聚焦人工智能、人才建设与风险韧性等三大领域，以期支撑 和驱动未来增长。 此外，中国 ...

Core Viewpoint - The Trump administration is drafting an executive order that will impose three major restrictions on commercial transactions involving Chinese innovative drug patents or rights, focusing on national security reviews by the Committee on Foreign Investment in the United States (CFIUS) [1][2]. Summary by Sections Executive Order Details - The draft includes three main provisions: 1. Inclusion of Chinese innovative drug BD transactions in the CFIUS mandatory review list, ending the previous "low-risk automatic exemption" practice [2]. 2. FDA will implement "racial sensitivity supplementary reviews" for drugs relying on Chinese clinical data, requiring at least 20% comparative data from non-Asian populations [2]. 3. Establishment of a "key drug domestic production fund" to provide production subsidies for 15 categories of drugs, including antibiotics and acetaminophen, while implementing a "domestic priority" principle in federal procurement [2]. Market Reaction - The market reacted swiftly to the policy risks, with the Hong Kong innovative drug index (HK1105) dropping 3.82% on September 11, 2025, and the A-share innovative drug sector (BK1106) declining 2.17%, with over 80% of stocks in the sector experiencing pullbacks [3]. - The following day, the indices showed signs of recovery, indicating investors' responses to policy uncertainties and rational corrections [3]. Globalization Trends - Despite the geopolitical risks, the trend of Chinese innovative drugs going global remains intact, with total license-out transactions to Europe and the U.S. reaching $9.43 billion as of September 2025 [3]. - Major transactions include a $950 million licensing deal between BeiGene and Royalty Pharma, and a $6 billion global licensing agreement between 3SBio and Pfizer, highlighting a shift towards milestone payments and regional licensing [3]. Industry Challenges - The domestic market faces challenges, with annual growth in medical insurance fund spending (approximately 12%) lagging behind the growth in innovative drug R&D investment (approximately 25%) [4]. - The average reduction in medical negotiations remains high at 54%, and commercial health insurance coverage for innovative drugs is below 15%, creating a supply-demand imbalance that necessitates going global [4]. Risk Resilience Assessment - Goldman Sachs has categorized Chinese innovative drug companies into three risk resilience tiers based on their sensitivity to policy changes and operational capabilities [4][5]. - Companies with mature global layouts exhibit the strongest resilience, while those heavily reliant on domestic markets show the weakest resilience [5][10]. Strategic Defense Framework - A three-dimensional defense system is proposed to address risks associated with the executive order, focusing on transaction review, data compliance, and supply chain security [13]. - Strategies include conducting national security risk pre-assessments for transactions over $50 million and establishing partnerships with U.S. law firms to navigate regulatory challenges [14][15]. Conclusion - The construction of a quantifiable "risk resilience index" is essential for Chinese innovative drugs in the global 2.0 era, emphasizing the need for companies to embed policy hedging clauses in transaction structures and consider racial diversity data in clinical stages [23].